^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
WU-NK-101
i
Other names: WU-NK-101, cytokine-induced memory-like NK cells, HCW9201 based cell therapy, W-NK1
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
HCW Biologics, Wugen
Drug class:
NK cell stimulant
Related drugs:
2ms
Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant (clinicaltrials.gov)
P1/2, N=62, Completed, Washington University School of Medicine | Recruiting --> Completed | N=110 --> 62 | Trial completion date: Oct 2028 --> Jun 2025 | Trial primary completion date: Oct 2028 --> Jun 2025
Trial completion • Enrollment change • Trial completion date • Trial primary completion date
|
cytarabine • cyclophosphamide • WU-NK-101
2ms
WUN101-01: A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
P1, N=9, Completed, Wugen, Inc. | Trial completion date: Jan 2025 --> Oct 2024 | Active, not recruiting --> Completed
Trial completion • Trial completion date
|
BCL2 (B-cell CLL/lymphoma 2)
|
WU-NK-101
6ms
Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant (clinicaltrials.gov)
P1/2, N=110, Recruiting, Washington University School of Medicine | Active, not recruiting --> Recruiting | N=62 --> 110 | Trial completion date: Nov 2025 --> Oct 2028 | Trial primary completion date: Nov 2025 --> Oct 2028
Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
|
cytarabine • cyclophosphamide • WU-NK-101
7ms
Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant (clinicaltrials.gov)
P1/2, N=62, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting | N=110 --> 62 | Trial completion date: Oct 2028 --> Nov 2025 | Trial primary completion date: Oct 2028 --> Nov 2025
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
cytarabine • cyclophosphamide • WU-NK-101
8ms
A Phase 1b Study of WU-NK-101 in Combination With Cetuximab (clinicaltrials.gov)
P1, N=30, Active, not recruiting, Wugen, Inc. | Recruiting --> Active, not recruiting
Enrollment closed
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600 • EGFR expression • RAS mutation
|
Erbitux (cetuximab) • WU-NK-101
1year
WUN101-01: A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
P1, N=9, Active, not recruiting, Wugen, Inc. | Trial completion date: Dec 2025 --> Jan 2025
Trial completion date
|
BCL2 (B-cell CLL/lymphoma 2)
|
WU-NK-101
over1year
WUN101-01: A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
P1, N=9, Active, not recruiting, Wugen, Inc. | Recruiting --> Active, not recruiting | N=24 --> 9
Enrollment closed • Enrollment change
|
BCL2 (B-cell CLL/lymphoma 2)
|
WU-NK-101
over1year
WUN101-01: A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) (clinicaltrials.gov)
P1, N=24, Recruiting, Wugen, Inc. | Trial primary completion date: Apr 2024 --> Dec 2024
Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2)
|
WU-NK-101
over1year
A "Prime and Expand" strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapy. (PubMed, Cancer Immunol Immunother)
The resulting "Prime and Expand" ML NK cells exhibited elevated metabolic capacity, stable epigenetic IFNG promoter demethylation, enhanced antitumor activity in vitro and in vivo, and superior persistence in NSG mice. Thus, the "Prime and Expand" strategy represents a simple feeder cell-free approach to streamline manufacturing of clinical-grade ML NK cells to support multidose and off-the-shelf ACT.
Journal
|
IFNG (Interferon, gamma) • IL18 (Interleukin 18) • IL15 (Interleukin 15) • IL21 (Interleukin 21) • IL7 (Interleukin 7)
|
WU-NK-101
over1year
A Phase 1b Study of WU-NK-101 in Combination With Cetuximab (clinicaltrials.gov)
P1, N=30, Recruiting, Wugen, Inc. | Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2025 --> Sep 2025
Enrollment open • Trial primary completion date • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene)
|
Erbitux (cetuximab) • WU-NK-101
2years
A Phase 1b Study of WU-NK-101 in Combination With Cetuximab (clinicaltrials.gov)
P1, N=30, Not yet recruiting, Wugen, Inc. | Phase classification: P1b --> P1 | Initiation date: Nov 2023 --> Jun 2024
Phase classification • Trial initiation date • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600 • EGFR expression • RAS mutation
|
Erbitux (cetuximab) • WU-NK-101
2years
WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Naturally Overcomes Tumor Microenvironment (TME) Metabolic Challenges, Retaining Anti-Tumor Potency (ASH 2023)
Overall, W-NK inherently survives and maintains function in the TME, a limiting factor for immune cell-based ACT. These data herald the promise of NK cell therapy; a Phase 1 clinical study of W-NK in acute myeloid leukemia is currently open and enrolling patients (NCT# 05470140).
SLC3A2 (Solute Carrier Family 3 Member 2) • SLC1A5 (Solute Carrier Family 1 Member 5) • SLC7A5 (Solute Carrier Family 7 Member 5) • TGFB1 (Transforming Growth Factor Beta 1) • SLC2A1 (Solute Carrier Family 2 Member 1)
|
WU-NK-101
Share via
